US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Yesterday's Top Gainers

785.65

+18.462.41%

Number of Gainers:34

Number of Losers:21

Number of Flat:2

PE:- -

High:798.05

Open:767.12

Low:767.09

Close:767.19

Loading ...

Li Auto (NasdaqGS:LI) Surges 35% with 30% Jump in February Deliveries

Simply Wall St.

RELX PLC Acquires Additional Treasury Shares

March 2025 Penny Stocks To Consider For Growth

Simply Wall St.

Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment

MT Newswires Live

BRIEF-Ocugen Announces Positive Opinion Of EMA’S Committee For Advanced Therapies For ATMP Classification

Unusually active option classes on open March 3rd

Ocugen Announces Positive Opinion of Ema’s Committee for Advanced Therapies for Atmp Classification for Novel Modifier Gene Therapy Candidate Ocu410 for Geographic Atrophy and Ocu410st for Stargardt Disease

THOMSON REUTERS

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Acurx Announces Publication of Nonclinical in Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects From Other Anti-Cdi Antibiotics

THOMSON REUTERS

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Mitsubishi Electric Automotive America Signs Agreement with Seeing Machines to Promote Guardian Generation 3 Driver Monitoring Technology Across the Americas

Top Premarket Decliners

MT Newswires Live

Li Auto's February Deliveries Increase 30%

MT Newswires Live

Mersana Therapeutics Q4 EPS USD -0.11

THOMSON REUTERS

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

Press Release: Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4563/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4563"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4563\",,,,,undefined,":{"symbol":"BK4563","market":"US","secType":"PLATE","nameCN":"Yesterday's Top Gainers","latestPrice":785.64606,"timestamp":1741723199999,"preClose":767.19,"halted":0,"volume":92073409,"delay":0,"changeRate":0.024057,"change":18.456055,"pbRate":2.279718,"amount":1467243520.224891,"amplitude":0.040352,"prevYearClose":733.5465,"fiveDayClose":763.9244,"twentyDayClose":769.1825,"turnoverRate":0.016638,"marketCap":141362657183,"floatMarketCap":81117188858.5,"peRate":47.877472},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4563\",,,,,undefined,":{"symbol":"BK4563","high":798.05176,"amplitude":0.040352,"preClose":767.19,"low":767.0943,"pbRate":"2.279718","latestPrice":785.64606,"volume":92073409,"delay":0,"open":767.1208,"prevYearClose":733.5465,"prevWeekClose":800.7308,"prevMonthClose":790.6026,"prevQuarterClose":733.5465,"fiveDayClose":763.9244,"twentyDayClose":769.1825,"sixtyDayClose":747.3299,"secType":"PLATE","market":"US","turnoverRate":0.016638,"peRate":47.877472,"marketCap":141362657183,"floatMarketCap":81117188858.5,"timestamp":1741723199999,"nameCN":"Yesterday's Top Gainers"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4563\",,,,undefined,":{"bkCode":"BK4563","up":34,"down":21,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4563\",pageSize:16,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516540276","title":"Li Auto (NasdaqGS:LI) Surges 35% with 30% Jump in February Deliveries","url":"https://stock-news.laohu8.com/highlight/detail?id=2516540276","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516540276?lang=en_us&edition=fundamental","pubTime":"2025-03-04 02:04","pubTimestamp":1741025097,"startTime":"0","endTime":"0","summary":"Li Auto posted an impressive 35% price increase in the last quarter, coinciding with a robust delivery growth reported in early 2025. The announcement on March 1, revealing a 29.7% increase in year-over-year vehicle deliveries for February totaling 26,263, spotlighted the company's accelerating momentum, which continued strong delivery numbers from January with nearly 30,000 vehicles. As the broader market grappled with 1.3% downturns amid economic uncertainties, Li Auto differentiated itself through consistent delivery growth, defying the trend impacting major indices like the Nasdaq, which faced a 4% decline in February. This contrast, set against a backdrop of concerns over trade policies and tariffs affecting other industries, underscores the resilience and expansion of the electric vehicle sector. The price uptick reflects positive investor sentiment, driven by Li Auto's performance and growth aspirations as it expands its market presence.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/li-auto-nasdaqgs-li-surges-180457502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Li Auto (NasdaqGS:LI) Surges 35% with 30% Jump in February Deliveries","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4503","BK4588","EVS.SI","BK4555","LI","BK4526","BK4585","BK4099","BK4548","BK4551","BK4563"],"gpt_icon":1},{"id":"2516024659","title":"RELX PLC Acquires Additional Treasury Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2516024659","media":"TIPRANKS","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516024659?lang=en_us&edition=fundamental","pubTime":"2025-03-04 01:28","pubTimestamp":1741022881,"startTime":"0","endTime":"0","summary":"RELX plc ( ($GB:REL) ) has provided an announcement. RELX PLC announced the purchase of 255,385 of its own ordinary shares through UBS AG London Br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/relx-plc-acquires-additional-treasury-shares-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/relx-plc-acquires-additional-treasury-shares-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["US2Y.BOND","RLX","US12M.BOND","BK4526","US7Y.BOND","US30Y.BOND","BK4551","US3Y.BOND","BK4075","US10Y.BOND","US5Y.BOND","US6M.BOND","BK4563"],"gpt_icon":0},{"id":"2516656760","title":"March 2025 Penny Stocks To Consider For Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2516656760","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516656760?lang=en_us&edition=fundamental","pubTime":"2025-03-04 01:04","pubTimestamp":1741021496,"startTime":"0","endTime":"0","summary":"As the U.S. stock market grapples with economic uncertainties and fluctuating indices, investors are increasingly exploring diverse opportunities for growth. Penny stocks, often associated with smaller or newer companies, continue to capture interest due to their potential for significant returns at lower price points. Despite being considered a somewhat outdated term, these stocks can offer substantial growth prospects when backed by solid financials and strong fundamentals.Overview: Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on the research, development, and commercialization of Alpha DaRT for treating solid cancer in Israel and the United States, with a market cap of $211.71 million.Overview: Wrap Technologies, Inc. is a public safety technology and services company that develops policing solutions for law enforcement and security personnel globally, with a market cap of $100.48 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/march-2025-penny-stocks-consider-170456976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SB","BK4213","PHX","PVL","DRTS","WRAP","TTI","BK4082","BK4563","BABB","BK4021","DRTSW","BK4539","BK4179","BK4209","SGHT"],"gpt_icon":0},{"id":"2516653170","title":"Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653170","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653170?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:22","pubTimestamp":1741018934,"startTime":"0","endTime":"0","summary":"Ocugen  said Monday that the European Medicines Agency's Committee for Advanced Therapies issued a positive opinion granting Advanced Therapy Medicinal Product classification for its OCU410 and OCU410ST gene therapy candidates, which are being developed to treat vision loss caused by geographic atrophy and Stargardt disease.Dosing in the Phase 2 portion of the OCU410 clinical trial has been completed, and Ocugen expects to begin a Phase 3 trial next year, with plans to pursue regulatory approval in the US and Europe in 2028.Last week, the US Food and Drug Administration endorsed Ocugen's plan to initiate a Phase 2/3 pivotal confirmatory trial for OCU410ST, which could support future biologics license and marketing authorization applications in the US and EU, respectively.If approved, OCU410 could become the first treatment available in Europe for geographic atrophy, a late-stage form of dry age-related macular degeneration. While two therapies are currently approved in the US, neither ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6522","IE00B19Z4B17.USD","BK4563","AEIS","IE0031619046.USD","IE00B7SZL793.SGD","BLZ.SI","BK4157","BK4139","IE00B66KJ199.SGD","OCGN","BK6088","BK4568"],"gpt_icon":0},{"id":"2516329226","title":"BRIEF-Ocugen Announces Positive Opinion Of EMA’S Committee For Advanced Therapies For ATMP Classification","url":"https://stock-news.laohu8.com/highlight/detail?id=2516329226","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516329226?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:53","pubTimestamp":1741013593,"startTime":"0","endTime":"0","summary":"BRIEF-Ocugen Announces Positive Opinion Of EMA’S Committee For Advanced Therapies For ATMP Classification March 3 (Reuters) - Ocugen Inc OCGN.O:OCUGEN ANNOUNCES POSITIVE OPINION OF EMA’S COMMITTEE FOR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM10Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","OCGN","BK4568"],"gpt_icon":0},{"id":"2516605632","title":"Unusually active option classes on open March 3rd","url":"https://stock-news.laohu8.com/highlight/detail?id=2516605632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516605632?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:40","pubTimestamp":1741012844,"startTime":"0","endTime":"0","summary":"Unusual total active option classes on open include: Vodafone (VOD), Allegro MicroSystems (ALGM), Canaan Inc (CAN), Li Auto (LI), Mosaic (MOS), Hut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-march-3rd-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-march-3rd-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0353189680.USD","BK4141","BK4563","LU0353189763.USD","BK4585","LU2380233275.USD","CAN","BK4099","BK4503","LU2087625088.SGD","EVS.SI","MOS","LI","BK4093","BK4551","BK4526","BK4132","BK4555","BK4595","ALGM","BK4588","LU0053671581.USD","BK4170","VOD","BK4548","BK4600","BK4532"],"gpt_icon":0},{"id":"2516639628","title":"Ocugen Announces Positive Opinion of Ema’s Committee for Advanced Therapies for Atmp Classification for Novel Modifier Gene Therapy Candidate Ocu410 for Geographic Atrophy and Ocu410st for Stargardt Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2516639628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516639628?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:00","pubTimestamp":1741010421,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM10Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4563","BK4139","OCGN"],"gpt_icon":0},{"id":"2516112639","title":"Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2516112639","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516112639?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:00","pubTimestamp":1741010400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March 03, 2025  -- Ocugen, Inc.  , a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the European Commission has provided a positive opinion from the European Medicines Agency’s  Committee for Advanced Therapies  for OCU410 and OCU410ST Advanced Therapy Medicinal Product  classification. OCU410 is a novel, multifunctional modifier gene therapy candidate being developed for the treatment of patients with vision loss due to geographic atrophy —an advanced stage of dry age-related macular degeneration —and OCU410ST is being developed for Stargardt disease due to ABCA4-related retinopathies.GA affects 2-3 million people in the United States  and Europe combined. There are two approved therapies in the U.S. that require frequent dosing , however neither therapy has been approved in Europe. Stargardt disease affects 100,000 people in the U.S. and Europe combined, and there are no approved treatments available globally.6-month data ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ocugen-announces-positive-opinion-ema-140000451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4532","BK4597","LU1917777945.USD","LU2237438978.USD","IE00B7SZL793.SGD","BK4563","LU0942090050.USD","BK4585","BK4516","LU2023250504.SGD","MAA","BK4157","CAT","BK4520","IE0031619046.USD","LU0868494617.USD","IE00BD6J9T35.USD","BK4149","LU1064131342.USD","IE00B66KJ199.SGD","IE00BSNM7G36.USD","LU0868494708.USD","LU1988902786.USD","OCGN","BK4215","LU2264538146.SGD","LU1974910355.USD","LU2106854487.HKD","AEIS","BK4568","ATMP","BK4588","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2516633675","title":"Acurx Announces Publication of Nonclinical in Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects From Other Anti-Cdi Antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516633675?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006829,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA7NS76Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACXP","BK4563","BK4539","BK4139"],"gpt_icon":0},{"id":"2516635992","title":"Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635992","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635992?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat  to other anti-CDI antibiotics in a germ-free mouse model. Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin -or metronidazole -treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activity. Notable differences were observed between the microbiome of IBZ- and fidaxomicin -treated groups, which may allow for differentiation of these two anti-CDI antibiotics in future studies. Results establish IBZ differentiating effects on the gut microbiome, indicating a more selective spectrum of microbiome alteration compared to broader-spectrum antibiotics like VAN and MET and a narrower spectrum of microbiome alteration compared to FDX. Preparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDI. IBZ has previously been granted FDA QIDP a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-announces-publication-nonclinical-vivo-130000861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4139","LU0128525689.USD","LU1267930227.SGD","BK4563","BK4131","BK4585","LU0742534661.SGD","GAIN","LU1989772840.SGD","LU0048573561.USD","LU1989771016.USD","MAA","ACXP","LU0251142724.SGD","BK4533","LU0251131958.USD","PK","NCI","BK4202","BK4218","LU1291159041.SGD","LU0310800965.SGD","LU1496350502.SGD","BK4215","BK4539","ECC","LU0052756011.USD","MET","BK4194","LU1989772923.USD","LU1571399168.USD","BK4135","BK4162","FDX","VRE","BK4588","IDSA"],"gpt_icon":0},{"id":"2516633492","title":"Mitsubishi Electric Automotive America Signs Agreement with Seeing Machines to Promote Guardian Generation 3 Driver Monitoring Technology Across the Americas","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633492","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516633492?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"Mitsubishi Electric Automotive America, Inc.  and Seeing Machines Limited representatives. MEAA has signed a Referral Agreement with Seeing Machines Limited to promote Seeing Machines’ Guardian Generation 3 driver monitoring solution across the Americas. . Guardian Generation 3 aftermarket system uses advanced computer monitoring technology to track signs of driver distraction and drowsiness. MASON, Ohio, March 03, 2025----Mitsubishi Electric Automotive America, Inc. , a leader in advanced automotive electrical and electronic systems, today announced it has signed a Referral Agreement with Seeing Machines Limited to promote Seeing Machines’ Guardian Generation 3 driver monitoring solution across the Americas.Following Mitsubishi Electric Mobility Corporation’s strategic investment in Seeing Machines in December 2024, this agreement leverages MEAA’s extensive aftermarket distribution network and customer relationships in the transport and logistics industries.Guardian Generation 3 will ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mitsubishi-electric-automotive-america-signs-130000356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4009","TMC","BK4182","BK4563","MIELF","MIELY","BK4168","DMS"],"gpt_icon":0},{"id":"2516384966","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2516384966","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516384966?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:47","pubTimestamp":1741006045,"startTime":"0","endTime":"0","summary":"23andMe Holding  shares were down 31% pre-bell Monday following a muted session.Li Auto  stock was 8.4% lower following a 3.7% loss in the previous session.Health In Tech  shares were down 8% after Friday's 1.2% gain.ADT  stock was 5.9% lower after the company said that a secondary offering of its shares held by entities managed by Apollo Global Management  was launched.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4173","BK4135","BK4526","LU0006061336.USD","LU1323610961.USD","APO","ME","LU0106831901.USD","BK4585","BK4503","IE0002270589.USD","BK7057","HIT","BK4548","IE00B19Z3B42.SGD","IE00B3S45H60.SGD","BK4099","BK4555","LI","LU1791807156.HKD","LU1668664300.SGD","EVS.SI","BK4165","BK4184","BK4588","BK4551","BK4563","BK4192","BK7095","ADT","LU0787776722.HKD","HIT.AU","LU0683600562.USD","BK4196","ADT.AU","IE00B19Z3581.USD","BK4121","IE00B775SV38.USD"],"gpt_icon":0},{"id":"2516268778","title":"Li Auto's February Deliveries Increase 30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516268778","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516268778?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:05","pubTimestamp":1741003536,"startTime":"0","endTime":"0","summary":"Li Auto's  deliveries increased about 30% to 26,263 units in February, according to a Sunday filing with the Hong Kong bourse.The car manufacturer has 500 retail stores scattered across 150 cities, with 488 servicing centers and company-authorized body and paint shops in 224 cities.Its super charging stations number 1,874 with 10,008 charging stalls in China, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1794554557.SGD","BK4503","02015","BK4526","BK4588","BK1588","BK4585","BK4551","BK4555","LI","BK4548","EVS.SI","BK1119","BK1539","BK4099","BK1575","BK4563","BK1587","LU1720050803.USD"],"gpt_icon":0},{"id":"2516268716","title":"Mersana Therapeutics Q4 EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2516268716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516268716?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:01","pubTimestamp":1741003283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nPLXDEBF30:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","MRSN","BK4139"],"gpt_icon":0},{"id":"2516687262","title":"Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687262","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687262?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:01","pubTimestamp":1741003260,"startTime":"0","endTime":"0","summary":"Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-Le. Initiated first expansion cohort in patients with triple-negative breast cancer  previously treated with at least one topoisomerase-1 inhibitor  ADC. Emiltatug Ledadotin In January 2025, Mersana announced positive initial Phase 1 clinical data for Emi-Le, the company’s lead Dolasynthen ADC candidate targeting B7-H4, from 130 patients who were enrolled in dose escalation and backfill cohorts as of a December 13, 2024 data cutoff. The company also announced that Emi-Le had received a second Fast Track designation from the U.S. Food and Drug Administration .In 2025, Mersana plans to initiate expansion enrollment at a second dose in patients with TNBC who have received one to four prior lines of treatment, including at least one prior topo-1 ADC. The company also plans to present additional Phase 1 clinical data from dose escalation and backfill cohorts in 2025.XMT-2056Mersana has continue","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mersana-therapeutics-provides-business-announces-120100840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4563","MRSN","BK4139"],"gpt_icon":0},{"id":"2516687935","title":"Press Release: Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687935","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687935?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update. KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026. Expect to progress next M4 positive allosteric modulator  program into the clinic by mid-2025. \"The first two months of 2025 have been productive for Neumora. We have analyzed the data set provided by KOASTAL-1 and made important amendments to help optimize the ongoing KOASTAL-2 and -3 studies based on the learnings. We believe these changes strengthen the studies and look forward to delivering topline data in 2026. We've also progressed enrollment in the Phase 1b signal-seeking study for NMRA-511 in Alzheimer's disease agitation and expect to advance our next M4 program into the clinic by mid-2025,\" said Paul L. Berns, chief executive officer, Neumora. \"With our industry-leading pipeline, strong financial","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4081","BK4007","LENZ","IE00B19Z4B17.USD","BK4145","IE00B66KJ199.SGD","BK4563","IE00B7SZL793.SGD","BK4139","CTS","IE0031619046.USD","PAM"],"gpt_icon":0}],"pageSize":16,"totalPage":18,"pageCount":11,"totalSize":274}]}}